Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Raises $20M

NEW YORK (GenomeWeb News) – Cellular Dynamics has raised $20 million, the stem cell technologies firm said in a regulatory document filed on Wednesday.

In a Form D filed with the US Securities and Exchange Commission, the company, which filed to go public last month, did not say how it planned to use proceeds from the raise or disclose the investors, but said that eight investors participated in the offering. The securities offered were in the form of debt; options, warrants, or other rights to acquire another security; and security to be acquired upon exercise of option, option warrant, or other right to acquire security.

Cellular Dynamics announced in June its plans to raise a maximum aggregate of $57.3 million in its public offering. Based in Madison, Wis., it develops stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking.

In 2011, the company raised $30 million in a Series B Preferred Stock financing round, and $40.6 million 2010 in Series B private equity funding.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.